DIGOXIN AS A RESCUE DRUG IN INTRA AORTIC BALLOON PUMP AND INOTROPE DEPENDENT PATIENTS
AbstractBackground: In absence of cardiac transplant program in our country, when patients with poorleft ventricular (LV) functions undergo coronary revascularisation surgery, they are on one ormore inotropic supports with intra aortic balloon pump (IABP) at the time of weaning off fromcardiopulmonary bypass (CPB). Post-operatively, due to the poor LV function, many of thesepatients become dependent on inotropic supports and IABP and eventually have a poor outcome.We used digoxin in these patients as a rescue drug, where more than one attempts to wean themoff IABP and inotropic support had failed. Objective of the study was to evaluate the efficacy ofdigoxin as a rescue drug in intra-aortic balloon pump (IABP) and inotropic support-dependent,post-CABG patients in terms of improvement in their left ventricular ejection fraction (LVEF),serum lactate and mixed venous oxygen saturation. Methods: It is a descriptive case seriesconducted at Department of Cardiac Anesthesia & Intensive Care, Armed Forces Institute ofCardiology and National Institute of Heart Diseases, Rawalpindi, Pakistan, from 1 Nov 2002 to 31Dec 2007. Thirty post-coronary re-vascularisation patients who were inotrope and IABPdependant and could not be weaned off from supports were given a trial of digoxin to see anyimprovement in the cardiac functions. Mixed venous oxygen saturation (SvO2), serum lactatelevels and left ventricular ejection fraction (LVEF) in the bed side echo were monitored at predigoxin stage and then at three intervals: at serum digoxin level of up to 0.5 ηg/ml; then up to 1.0ηg/ml and then up to 1.5 ηg/ml. Paired sample t-test was applied and 2-tailed significance wascalculated. Results: Significant improvement was seen in the mean SvO2, serum lactate levels andLVEF when patient’s serum digoxin level were around 1.5 ηg/dL. Clinically, 20 out of 30 patients(66.67%) improved with digoxin administration and were ultimately weaned off from IABP andinotropic supports. There was no significant correlation between patient’s improvement andpresence of diabetes mellitus or hypertension. However, pre-operative IABP placement had asignificant correlation as 6 out of 8 patients (75%) were successfully weaned off at digoxin levelsaround 1.5 ηg/mL. Conclusion: Improvement in significant number of patients suggests thatdigoxin can be used as a rescue drug in IABP and inotropic support dependent patients afterCABG surgery especially in countries where heart transplant program does not exist. However,more clinical trials with larger sample size are recommended for further evaluation.Keywords: Digoxin, CABG, IABP-dependent, Inotrope-dependent
John R, Rajasinghe HA, Chen JM, Weinberg AD, Sinha P,
Mancini DM, et al. Long-term outcomes after cardiac
transplantation: an experience based on different eras of
immunosuppressive therapy. Ann Thorac Surg 2001;72:440–9.
Zubiate P, Kay JH, Mendez AM. Myocardial
revascularization for the patient with drastic impairment of
function of the left ventricle. J Thorac Cardiovasc Surg
Passamani E, Davis KB, Gillespie MJ, Killip T. A
randomized trial of coronary artery bypass surgery. Survival
of patients with a low ejection fraction. N Engl J Med
Christakis GT, Weisel RD, Fremes SE, Ivanov J, David TE,
Goldman BS, et al. Coronary artery bypass grafting in
patients with poor ventricular function. Cardiovascular
Surgeons of the University of Toronto. J Thorac Cardiovasc
Breisblatt WM, Stein KL, Wolfe CJ, Follansbee
WP, Capozzi J, Armitage JM, et al. Acute myocardial
dysfunction and recovery: a common occurrence after
coronary bypass surgery. J Am Coll Cardiol 1990;15:1261–9.
Mangano DT. Alteration of ventricular function during
coronary artery surgery. Acta Chir Scand Suppl
Cox DR. Regression models and life tables. J R Stat Soc
Lemeshow S, Hosmer DW. A review of goodness of fit
statistics for use in the development of logistic regression
models. Am J Epidemiol 1982;115:92–106.
Carr JA, Haithcock BE, Paone G, Bernabei AF, Silverman
NA. Long-term outcome after coronary artery bypass
grafting in patients with severe left ventricular dysfunction.
Ann Thorac Surg 2002;74:1531–6.
Ascione R, Narayan P, Rogers CA, Lim KH, Capoun R,
Angelini GD. Early and midterm clinical outcome in patients
with severe left ventricular dysfunction undergoing coronary
artery surgery. Ann Thorac Surg 2003;76:793–9.
Topkara VK, Cheema FH, Kesavaramanujam S, Mercando
ML, Cheema AF, et al. Coronary Artery Bypass Grafting in
Patients With Low Ejection Fraction. Circulation 2005;112:I-
Islamoğlu F, Apaydin AZ, Ozbaran M, Yüksel M, Telli A,
Durmaz I. Predictors of outcome after coronary bypass
surgery in patients with left ventricular dysfunction. Anadolu
Kardiyol Derg 2002;2(1):26–34.
Bolooki H. Clinical application of Intra-Aortic Ballon Pump.
Mount Kisco, New York: Futura Publishing; 1984.
Sarnoff SJ, Braunwald E, Welch GH Jr, Case RB, Stainsby
WN, Macruz R. Hemodynamic determinants of oxygen
consumption of the heart with special reference to the tension
time index. Am J Physiol 1958;192:148–56.
Akyurekli Y, Taichmann JC, Keon WJ. Effectivness of intra
aortic balloon counteroulsation and systolic unloading. Can J
Packer M. How should physicians view heart failure? The
philosophical and physiological evolution of three conceptual
models of the disease. Am J Cardiol 1993;71:3C–11C.
Bristow MR. The adrenergic nervous system in heart failure.
[Editorial] N Engl J Med 1984;311:850–1.
Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac
myocyte necrosis induced by angiotensin II. Circ Res
Samad K, Khan FA. The role of prophylactic Intra-Aortic
Balloon Pump Counterpulsation (IABP) in emergency noncardiac surgery. J Pak Med Assoc 2006;56:42–3.
J Ayub Med Coll Abbottabad 2010;22(2)
Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White
HD, Talley JD, et al. Early revascularization in acute
myocardial infarction complicated by cardiogenic shock.
SHOCK Investigators. Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock. N Engl J Med
Dietl CA, Berkeimer MD, Woods EL, Gilbert CL, Pharr
WF, Benoit CH. Efficacy and cost-effectiveness of
preoperative IABP in patients with ejection fraction of 0.25
or less. Ann Thorac Surg 1996;62:401–8.
Qureshi MRK, Waqas M, Saqlain MU, Shahbaz A, Khan J,
Sami W. Use of IABP during Intra or Postoperative Period of
Coronary Artery. J Fatima Jinnah Med Coll Lahore
Christenson JT, Simonet F, Badel P, Schmuziger M. Optimal
timing of preoperative intra-aortic balloon pump support in
high-risk coronary patients. Ann Thorac Surg 1999;68:934–9.
Christenson JT, Badel P, Simonet F, Schmuziger M.
Preoperative intraaortic balloon pump enhances cardiac
performance and improves the outcome of redo CABG. Ann
Thorac Surg 1997;64:1237–44.
Gutfinger DE, Ott RA, Miller M, Selvan A, Codini MA,
Alimadadian H, Tanner TM. Aggressive preoperative use of
intraaortic balloon pump in elderly patients undergoing
coronary artery bypass grafting. Ann Thorac Surg
Kapadia FN, Vadi S, Bajan K, Shukla U. A two years
outcome analysis of patients on intra-aortic balloon pump in
a tertiary care center. Indian J Crit Care Med [serial online]
[cited 2008 Jan 1];8:157-61. Available
Withering W. An account of the foxglove and some of its
medical uses, with practical remarks on dropsy and other
diseases. In: Willius FA, Keys TE, eds. Classics of
cardiology: a collection of classic works on the heart and
circulation with comprehensive biographic accounts of the
authors. Malabar, Fla: Krieger; 1983. 747–58.
The effect of digoxin on mortality and morbidity in patients
with heart failure. The Digitalis Investigation Group. N Engl
J Med 1997;336:525–33.
Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison
MC, Jolly MK. Randomized study assessing the effect of
digoxin withdrawal in patients with mild to moderate chronic
congestive heart failure: results of the PROVED trial.
PROVED Investigative Group. J Am Coll Cardiol
Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams
KF, Cody RJ, et al. Withdrawal of digoxin from patients with
chronic heart failure treated with angiotensin-convertingenzyme inhibitors. RADIANCE Study. N Engl J Med
Alicandri C, Fariello R, Boni E, Zaninelli A, Castellano M,
Beschi M, et al. Captopril versus digoxin in mild-moderate
chronic heart failure: a crossover study. J Cardiovasc
Pharmacol 1987;9(suppl 2):S61–7.
Gheorghiade M, Hall V, Lakier JB, Goldstein S.
Comparative hemodynamic and neurohormonal effects of
intravenous captopril and digoxin and their combinations in
patients with severe heart failure. J Am Coll Cardiol
van Veldhuisen DJ, Man in't Veld AJ, Dunselman PH, Lok
DJ, Dohmen HJ, Poortermans JC, et al. Double-blind
placebo-controlled study of ibopamine and digoxin in
patients with mild to moderate heart failure: results of the
Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll
Eichhorn EJ, Gheorghiade M. Digoxin. Prog Cardiovasc Dis
Ahmed A. Digoxin and reduction in mortality and
hospitalization in geriatric heart failure: importance of low
doses and low serum concentrations. J Gerontol A Biol Sci
Med Sci 2007;62:323–9.
Hoppe UC, Erdmann E. Digitalis in heart failure! Still
applicable? Z Kardiol 2005;94:307–11.
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM.
Association of serum digoxin concentration and outcomes in
patients with heart failure. JAMA 2003;289:871–8.
Wang L, Song S. Digoxin may reduce the mortality rates in
patients with congestive heart failure. Med Hypotheses
Dec GW. Digoxin remains useful in the management of
chronic heart failure. Med Clin North Am 2003;87:317–37.
Riaz K, Forker AD. Digoxin use in congestive heart failure.
Current status. Drugs 1998;55:747–58.